Figure 7. Tigecycline shows activity against human Burkitt's lymphoma xenografts.

A. Relative cell viability (top) and cell numbers (bottom) for four Burkitt's lymphoma cell lines treated with the indicated doses of Tigecycline for 48 hrs. Values are represented as in Figure 3D. B. Left: Raji cells were injected subcutaneously into the flank of nude mice. Starting at day 12, when tumors were measurable, mice were injected intra-peritoneally (i.p.) twice per day (b.i.d.) with either 100 mg/kg Tigecycline or vehicle control. Tumor volume was assessed using a caliper at the indicated days. At day 35, mice were sacrificed and tumors collected for further analysis. Right: mean tumor volume at day 35 in vehicle versus Tigecycline-treated mice. Values are shown as the mean ± standard error of the mean (s.e.m.). * p < 0.05, as determined by student's t-test. C. Representative images of subcutaneous tumors from vehicle or tigecyline-treated mice at day 35. Scale bar: 1cm. D. Representative H&E- and Ki-67-stained sections from vehicle or tigecyline-treated mice at 10X magnification. Scale Bar: 100 μm.